See related Exjade dispersible tab[Ò×½âèF ¿ÉÈÜåV] information |
|
ÑuÔìÉÌ |
Novartis |
´úÀí/½›äNÉÌ |
Novartis |
³É·Ý |
Deferasirox |
ßm‘ªÖ¢ |
Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult & children ≥ 2 years. |
ÓÃÁ¿ |
Recommended initial daily dose: 20 mg/kg. Patients receiving >14 mL/kg/month of packed RBC (>4 u/month) & for reduction of Fe overload Initially 30 mg/kg daily. Patients receiving <7 mL/kg/month of packed RBC (<2 u/month) & for maintenance of Fe level Initially 10 mg/kg daily. For patients well managed on treatment with deferoxamine Consider a starting dose of Exjade that is numerically ½ that of the deferoxamine dose. Monitor serum ferritin monthly to assess patient's response to therapy. Maintenance daily dose: May be adjusted if necessary every 3-6 month based on ferritin trends. Dose adjustments should be made in steps 5-10 mg/kg. Interrupt treatment if serum ferritin falls consistently below 500 mcg/L. Max daily dose: 30 mg/kg. |
ß^Á¿ |
View Exjade[Ò×½âèF] overdosage for action to be taken in the event of an overdose. |
Ó÷¨ |
Should be taken on an empty stomach (Take on an empty stomach at least 30 mins before meals, preferably at the same time daily. Disperse the tab by stirring in 100-200 mL of water or orange juice until a fine susp is obtained. After the susp has been drunk, any residue must be resuspended in a small vol of water or orange juice & drunk. Do not chew or swallow the tab.). |
ÃÀ‡øÊ³Æ·ËŽÎï¹ÜÀí¾ÖÖ®‘ÑÔеȼ‰ |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
½û¼É |
[Click for Exjade[Ò×½âèF] detailed prescribing infomation] |
×¢ÒâÊÂí— |
Renal & hepatic impairment. Assess serum creatinine prior to therapy & monthly thereafter. Monitor liver function & proteinuria monthly. Interrupt therapy if severe rash develops. Perform auditory & ophth testing before treatment & at regular intervals. Monitor serum ferritin monthly. Monitor body weight & longitudinal growth at regular intervals in children. Pregnancy & lactation. Not to be combined with other Fe chelator therapy. Not recommended in rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption. |
²»Á¼·´‘ª |
Headache, diarrhea, constipation, vomiting, nausea, abdominal pain, abdominal distension, dyspepsia, elevated transaminases, rash, pruritus, proteinuria, increased serum creatinine.
View ADR Monitoring Website[…¢é†ËŽÎï²»Á¼·´‘ª±Oœy±í¸ñ] |
½»»¥×÷Óà |
Al-containing antacids.
View more drug interactions with Exjade[Ò×½âèF] |
ƒ¦´æ |
View Exjade[Ò×½âèF] storage conditions for details to ensure optimal shelf-life. |
ÃèÊö |
View Exjade[Ò×½âèF] description for details of the chemical structure and excipients (inactive components). |
×÷ÓÃ |
View Exjade[Ò×½âèF] mechanism of action for pharmacodynamics and pharmacokinetics details. |
±¾ÉÌÆ·Ö®ÊÐÊÛÒŽ¸ñ |
„©ÐÍ |
°üÑb |
ˆDƬ |
Exjade ·ÖÉ¢åV |
Exjade 125 mg x 28's |
 |
Exjade 250 mg x 28's |
Exjade 500 mg x 28's |
|
|
Manufacturer: |
Novartis |
Distributor: |
Novartis |
|
|
|
ÒÔÏÂÊÇ¡°È«ÇòÒ½Ò©¡±Ïêϸ×ÊÁÏ |
|
|
|